Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Finek, J. [1 ,2 ]
Poprach, A. [3 ,4 ]
Melichar, B. [5 ,6 ]
Kopecky, J. [7 ,8 ]
Zemanova, M. [7 ,8 ]
Buchler, T. [7 ,9 ]
Kopeckova, K. [10 ,11 ]
Mlcoch, T. [12 ]
Dolezal, T. [4 ,13 ]
Fiala, O. [1 ,2 ]
机构：
[1] Charles Univ Prague, Teaching Hosp Pilsen, Dept Radiotherapy & Oncol, Plzen, Czech Republic
[2] Charles Univ Prague, Fac Med Pilsen, Plzen, Czech Republic
[3] Masaryk Univ, Masaryk Mem Canc Inst, Clin Comprehens Canc Care, Brno, Czech Republic
[4] Masaryk Univ, Fac Med, Brno, Czech Republic
[5] Palacky Univ, Fac Med & Dent, Olomouc, Czech Republic
[6] Univ Hosp, Olomouc, Czech Republic
[7] Charles Univ Prague, Fac Med 1, Oncol, Prague, Czech Republic
[8] Gen Univ Hosp, Prague, Czech Republic
[9] Thomayer Hosp, Prague, Czech Republic
[10] Univ Hosp Motol, Dept Oncol, Prague, Czech Republic
[11] Charles Univ Prague, Fac Med 2, Prague, Czech Republic
[12] Inst Hlth Econ & Technol Assessment, HTA Dept, Prague, Czech Republic
[13] Masaryk Univ, Inst Hlth Econ & Technol Assessment, Dept Pharmacol, Prague, Czech Republic
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
957P
引用
收藏
页码：387 / 387
页数：1
相关论文
共 50 条
  • [21] DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
    Peters, Inga
    Dubrowinskaja, Natalia
    Abbas, Mahmoud
    Seidel, Christoph
    Kogosov, Michael
    Scherer, Ralph
    Gebauer, Kai
    Merseburger, Axel S.
    Kuczyk, Markus A.
    Gruenwald, Viktor
    Serth, Juergen
    PLOS ONE, 2014, 9 (03):
  • [22] Use of early tumor shrinkage as a response to VEGF inhibitors as a predictor of progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Gruenwald, Viktor
    Seidel, Christoph
    Fenner, Martin
    Woike, Michael
    Kalanovic, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] ACTIVITY OF SUNITINIB AS THIRD-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) (JAPAN)
    Nozawa, M.
    Mochida, Y.
    Nishigaki, K.
    Nagae, S.
    Uemura, H.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (03) : I11 - I11
  • [24] Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma
    Negrier, S.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Korytowsky, B.
    Sandin, R.
    Charbonneau, C.
    Michaelson, M. D.
    Figlin, R. A.
    Motzer, R. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (10) : 1766 - 1771
  • [25] Radiological Response and Neutrophil-to-Lymphocyte Ratio as Predictive Factors for Progression-Free and Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
    Kucharz, Jakub
    Dumnicka, Paulina
    Giza, Agnieszka
    Demkow, Urszula
    Kusnierz-Cabala, Beata
    Demkow, Tomasz
    Wiechno, Pawel
    MEDICAL SCIENCE AND RESEARCH, 2019, 1153 : 31 - 45
  • [26] P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma
    Sekino, Yohei
    Takemoto, Kenshiro
    Murata, Daiki
    Babasaki, Takashi
    Kobatake, Kohei
    Kitano, Hiroyuki
    Ikeda, Kenichiro
    Goto, Keisuke
    Inoue, Shogo
    Hayashi, Tetsutaro
    Taniyama, Daiki
    Shigeta, Masanobu
    Kuraoka, Kazuya
    Mita, Koji
    Kaneko, Mayumi
    Sentani, Kazuhiro
    Oue, Naohide
    Teishima, Jun
    ANTICANCER RESEARCH, 2021, 41 (09) : 4287 - 4294
  • [27] CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma
    Sekino, Yohei
    Takemoto, Kenshiro
    Murata, Daiki
    Babasaki, Takashi
    Kobatake, Kohei
    Kitano, Hiroyuki
    Ikeda, Kenichiro
    Goto, Keisuke
    Inoue, Shogo
    Hayashi, Tetsutaro
    Taniyama, Daiki
    Shigeta, Masanobu
    Kuraoka, Kazuya
    Mita, Koji
    Kaneko, Mayumi
    Sentani, Kazuhiro
    Oue, Naohide
    Teishima, Jun
    ANTICANCER RESEARCH, 2021, 41 (10) : 4875 - 4883
  • [28] Hand-Foot Syndrome and Progression-Free Survival in Patients Treated with Sunitinib for Metastatic Clear Cell Renal Cell Carcinoma
    Kucharz, Jakub
    Budnik, Monika
    Dumnicka, Paulina
    Pastuszczak, Maciej
    Kusnierz-Cabala, Beata
    Demkow, Tomasz
    Popko, Katarzyna
    Wiechno, Pawel
    ADVANCES IN MEDICINE AND MEDICAL RESEARCH, 2019, 1133 : 35 - 40
  • [29] Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (LT-OS) with sunitinib in 1,059 patients, treated on clinical trials, with metastatic renal cell carcinoma (mRCC)
    Motzer, R. J.
    Escudier, B.
    Bukowski, R.
    Rini, B. I.
    Hutson, T. E.
    Barrios, C. H.
    Lin, X.
    Fly, K.
    Matczak, E.
    Gore, M. E.
    BJU INTERNATIONAL, 2012, 109 : 8 - 8
  • [30] The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC)
    Kucharz, Jakub
    Dumnicka, Paulina
    Kusnierz-Cabala, Beata
    Demkow, Tomasz
    Wiechno, Pawel
    MEDICAL ONCOLOGY, 2019, 36 (02)
12345